Els Wauters

9.2k total citations · 2 hit papers
58 papers, 2.4k citations indexed

About

Els Wauters is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Els Wauters has authored 58 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 23 papers in Oncology and 9 papers in Surgery. Recurrent topics in Els Wauters's work include Lung Cancer Treatments and Mutations (12 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Lung Cancer Research Studies (7 papers). Els Wauters is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Lung Cancer Research Studies (7 papers). Els Wauters collaborates with scholars based in Belgium, United States and United Kingdom. Els Wauters's co-authors include Johan Vansteenkiste, Diether Lambrechts, Bram Boeckx, Adrian Liston, Birgit Weynand, Paul De Leyn, Oliver T. Burton, Bernard Thienpont, Herbert Decaluwé and Sara Aibar and has published in prestigious journals such as Nature, Nature Medicine and Nature Genetics.

In The Last Decade

Els Wauters

57 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phenotype molding of stromal cells in the lung tumor microenvironment

2018 1.0k citations Diether Lambrechts, Els Wauters et al. Nature Medicine profile →
MET is required for the recruitment of anti-tumoural neutrophils

2015 378 citations Els Wauters et al. profile →

Peers

Countries citing papers authored by Els Wauters

Since Specialization

Citations

This map shows the geographic impact of Els Wauters's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Els Wauters with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Els Wauters more than expected).

Fields of papers citing papers by Els Wauters

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Els Wauters. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Els Wauters. The network helps show where Els Wauters may publish in the future.

Co-authorship network of co-authors of Els Wauters

This figure shows the co-authorship network connecting the top 25 collaborators of Els Wauters. A scholar is included among the top collaborators of Els Wauters based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Els Wauters. Els Wauters is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1853MO Efficacy and safety of rilvegostomig, an anti-PD-1/TIGIT bispecific antibody, for checkpoint inhibitor (CPI)-naïve metastatic non-small cell lung cancer (mNSCLC): ARTEMIDE-01 2025 ·Annals of Oncology ·Byoung Chul Cho, J.T.J.N. Hiltermann, Hiroki Izumi, Mariana Brandão, (unknown), Pongwut Danchaivijitr, Enriqueta Felip, Gwo Fuang Ho, (unknown), Yongsheng Li, (unknown), (unknown), Els Wauters, (unknown), Tatsuya Yoshida, (unknown), Ikbel Achour, (unknown), (unknown), Yulei Wang	0
2	Proteolytic inactivation of CXCL12 in the lungs and circulation of COVID-19 patients 2023 ·Cellular and Molecular Life Sciences ·Seppe Cambier, (unknown), Noëmie Pörtner, Mieke Metzemaekers, (unknown), Erik Martens, Janne Kaes, (unknown), Cato Jacobs, Pierre Van Mol, Els Wauters, Philippe Meersseman, Greet Hermans, Rafael Elias Marques, Bart Vanaudenaerde, Robin Vos, Joost Wauters, Mieke Gouwy, Paul Proost	6
3	1446P Preliminary efficacy and safety of rilvegostomig (AZD2936), a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-pretreated advanced/metastatic non-small-cell lung cancer (NSCLC): ARTEMIDE-01 2023 ·Annals of Oncology ·Mariana Brandão, J.T.J.N. Hiltermann, Els Wauters, Benjamin Solomon, (unknown), Enriqueta Felip, Eelke Gort, Hiroki Izumi, Dongwook Kim, (unknown), Kristoffer Staal Rohrberg, (unknown), Tatsuya Yoshida, (unknown), (unknown), Ikbel Achour, (unknown), Francesca Aroldi, Byoung Chul Cho	6
4	Position statement on the management of the immune checkpoint inhibitor-induced colitis via multidisciplinary modified Delphi consensus 2023 ·European Journal of Cancer ·(unknown), Aranzazu Jauregui-Amezaga, (unknown), Sandrine Aspeslagh, Jeroen Dekervel, Els Wauters, Marc Peeters, João Sabino, (unknown), Michaël Somers, Anne Hoorens, (unknown), Triana Lobatón	6
5	Treatment of unresectable stage III NSCLC: Real world cohort study and literature review 2023 ·Cancer Treatment and Research Communications ·(unknown), Maarten Lambrecht, Patrick Berkovic, Christophe Dooms, Kristiaan Nackaerts, (unknown), Johan Vansteenkiste, Els Wauters	3
6	Hemolytic anemia caused by alectinib, an Anaplastic Lymphoma Kinase (ALK) inhibitor: A case report 2022 ·SHILAP Revista de lepidopterología ·Robina Aerts, (unknown), (unknown), M. Beckers, Christophe Dooms, Els Wauters, Kristiaan Nackaerts	1
7	Radiologic and Histologic Correlates of Early Interstitial Lung Changes in Explanted Lungs 2022 ·Radiology ·Stijn E. Verleden, Arno Vanstapel, Joseph Jacob, (unknown), Jeroen Hendriks, Laurens J. Ceulemans, Dirk Van Raemdonck, Laurens De Sadeleer, Robin Vos, Johanna M. Kwakkel‐van Erp, Arne Neyrinck, Geert M. Verleden, Matthieu Boone, Wim Janssens, Els Wauters, Birgit Weynand, Danny Jonigk, Johny Verschakelen, Wim Wuyts	11
8	Case report: BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib in ALK-rearranged lung adenocarcinoma 2022 ·Frontiers in Oncology ·(unknown), Els Wauters, (unknown), (unknown), (unknown), (unknown), Nicky D’Haene, (unknown), Thierry Vander Borght, Benoı̂t Rondelet, Sebahat Ocak	4
9	Early lung ultrasound assessment for the prognosis of patients hospitalized for COVID-19 pneumonia. A pilot study 2021 ·Respiratory Medicine and Research ·Alexandros Kalkanis, Els Wauters, Dries Testelmans, Jonas Yserbyt, Natalie Lorent, Zafeiris Louvaris, Laurent Godinas, Pierre Van Mol, Joost Wauters, (unknown), Christophe Dooms	2
10	Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2 2021 ·Nature Genetics ·Jim Baggen, Leentje Persoons, Els Vanstreels, Sander Jansen, Dominique Van Looveren, Bram Boeckx, (unknown), (unknown), Dirk Jochmans, Joost Wauters, Els Wauters, Bart Vanaudenaerde, Diether Lambrechts, Johan Neyts, Kai Dallmeier, Hendrik Jan Thibaut, Maarten Jacquemyn, Piet Maes, Dirk Daelemans	134
11	ES01.01 Chemotherapy is Strictly Additive to Immunotherapy 2019 ·Journal of Thoracic Oncology ·Johan Vansteenkiste, Els Wauters	1
12	Current status of immune checkpoint inhibition in early-stage NSCLC 2019 ·Annals of Oncology ·Johan Vansteenkiste, Els Wauters, Bart Reymen, Christoph Ackermann, Solange Peters, Dirk De Ruysscher	96
13	Phenotype molding of stromal cells in the lung tumor microenvironment breakdown → 2018 ·Nature Medicine ·Diether Lambrechts, Els Wauters, Bram Boeckx, Sara Aibar, David Nittner, Oliver T. Burton, Ayse Bassez, Herbert Decaluwé, Andreas Pircher, Kathleen Van den Eynde, Birgit Weynand, Erik Verbeken, Paul De Leyn, Adrian Liston, Johan Vansteenkiste, Peter Carmeliet, Stein Aerts, Bernard Thienpont	1037
14	RNA-sequencing in non-small cell lung cancer shows gene downregulation of therapeutic targets in tumor tissue compared to non-malignant lung tissue 2018 ·Radiation Oncology ·Kobe Reynders, Els Wauters, Matthieu Moisse, Herbert Decaluwé, Paul De Leyn, Stéphanie Peeters, Maarten Lambrecht, Kristiaan Nackaerts, Christophe Dooms, Wim Janssens, Johan Vansteenkiste, Diether Lambrechts, Dirk De Ruysscher	6
15	Prospects and progress of atezolizumab in non-small cell lung cancer 2017 ·Expert Opinion on Biological Therapy ·Johan Vansteenkiste, Els Wauters, Keunchil Park, Achim Rittmeyer, Alan Sandler, Alexander I. Spira	12
16	Transcriptome Sequencing of Tumor vs. Surrounding Non-Malignant Lung Tissue in Non-Small Cell Lung Cancer 2015 ·Journal of Thoracic Oncology ·Kobe Reynders, Els Wauters, Johan Vansteenkiste, Herbert Decaluwé, Paul De Leyn, Kristiaan Nackaerts, Stéphanie Peeters, Christophe Dooms, Wim Janssens, Diether Lambrechts, Dirk De Ruysscher	1
17	Variants in the 15q24/25 Locus Associate with Lung Function Decline in Active Smokers 2013 ·PLoS ONE ·Firdaus A. A. Mohamed Hoesein, Els Wauters, Wim Janssens, Harry J.M. Groen, Joanna Smolonska, Cisca Wijmenga, Dirkje S. Postma, H. Marike Boezen, Pim A. de Jong, Marc Decramer, Jan‐Willem J. Lammers, Diether Lambrechts, Pieter Zanen	3
18	Influence of 23 coronary artery disease variants on recurrent myocardial infarction or cardiac death: the GRACE Genetics Study 2012 ·European Heart Journal ·Els Wauters, Kathryn Carruthers, Ian Buysschaert, Donald R. Dunbar, Gilian Peuteman, Ann Belmans, Andrzej Budaj, Frans Van de Werf, Diether Lambrechts, Keith A.A. Fox	32
19	Inflammation of unknown origin versus fever of unknown origin: two of a kind 2008 ·Acta Clinica Belgica ·Els Wauters, David Ruttens, (unknown), (unknown), Daniël Knockaert, Steven Vanderschueren	5
20	Modification of ventricular fibrillation thresholds after sympatholytic drugs in the dog. 1972 ·PubMed ·(unknown), Els Wauters	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact